This protocol demonstrates a novel method for applying gene therapies to subpopulations of cells in neonatal rats at postnatal ages 5-10 days by injecting an anterograde chemogenetic modifier into the somatomotor cortex and a retrogradely transportable Cre recombinase into the cervical spinal cord.
Successfully tackling the obstacles that constrain research on neonatal rats is important for studying the differences in outcomes seen in pediatric spinal cord injuries (SCIs) compared to adult SCIs. In addition, reliably introducing therapies into the target cells of the central nervous system (CNS) can be challenging, and inaccuracies can compromise the efficacy of the study or therapy. This protocol combines viral vector technology with a novel surgical technique to accurately introduce gene therapies into neonatal rats at postnatal day 5. Here, a virus engineered for retrograde transport (retroAAV2) of Cre is introduced at the axon terminals of corticospinal neurons in the spinal cord, where it is subsequently transported to the cell bodies. A double-floxed inverted orientation (DIO) designer receptor exclusively activated by designer drug(s) (DREADD) virus is then injected into the somatomotor cortex of the brain. This double-infection technique promotes the expression of the DREADDs only in the co-infected corticospinal tract (CST) neurons. Thus, the simultaneous co-injection of the somatomotor cortex and cervical CST terminals is a valid method for studying the chemogenetic modulation of recovery following cervical SCI models in neonatal rats.
While SCI is a relatively rare occurrence in the pediatric population, it is particularly traumatic and causes a permanent disability requiring immense logistical foresight. Furthermore, a higher proportion of pediatric SCIs is classified as cervical and complete compared to the adult population1,2. A hallmark across mammalian species is that neonates recover notably better from SCI than adults, and this offers an opportunity to assess the driving mechanisms for recovery in younger populations3,4,5. Despite this, there are fewer multimodal studies tackling neonate and infant rodent research, partly due to the added difficulty of accurately targeting select populations of neurons in the much tighter anatomical landmarks of younger animals6. This article focuses on the direct injection of highly efficient anterograde and retrograde adeno-associated vectors into the rat spinal cord to modulate major motor pathways with the application of Cre-dependent-DREADDs, expanding the reach of multimodal regeneration studies.
Viral vectors are important biological tools with a breadth of applications, including the introduction of genetic material to substitute for target genes, upregulate growth proteins, and trace the anatomical landscape of the CNS7,8,9. Many of the anatomical details of spinal motor pathways have been studied using classical tracers, i.e., biotinylated dextran amine. While traditional tracers have been instrumental in unearthing neuroanatomy, they are not without their disadvantages: they indiscriminately label pathways even if correctly injected, and studies have found that they are taken up by damaged axons10,11,12. Consequently, this could lead to incorrect interpretations in regeneration studies where severed axons could be mistaken for regenerating fibers.
The following method utilizes the two-viral vector system recently popularized in modulation studies, with two different viral vectors in two separate areas of the same neuron13,14. The first is a vector that locally infects the cell bodies of projection neurons. The other is a retrograde vector being transported from the axon terminals of the projection neurons (Figure 1). The retrograde vector carries Cre recombinase, and the local vector incorporates the "Cre-On" double-floxed sequence in which a fluorescent protein (mCherry) is encoded. The native transgene expressing both hM3Dq and mCherry is inverted relative to the promoter and is flanked by two LoxP sites (Figure 2). Thus, mCherry is only expressed in the doubly transduced projection neurons where Cre recombinase induces a recombination event between the LoxP sites, flipping the orientation of the transgene into the appropriate reading frame and allowing the expression of both the DREADD and the fluorescent protein. Once the viral transgene is in the correct orientation, and when applicable, the DREADDs can transiently induce neuromodulation through a separately injected ligand, i.e., clozapine-N-oxide. The protocol was designed to authenticate inducible neuromodulation research in neonates, wherein DREADDS are injected to modulate the CSTs selectively. The two-viral system acts as an insurance policy, ensuring that every DREADD-positive cell is traceable under fluorescence with high fidelity to validate the injections.
This method also helps to bridge the gap in neonatal research. Pediatric SCI presents its challenges, and research analyzing regeneration, sprouting, or plasticity should emphasize the differences between neonates and adults3,15,16,17. By optimizing the surgical procedure and performing prior anatomical studies with Nissl staining, the coordinates for both the cranial and spinal injections were validated. The aim was to provide a method for dual injections into a neonatal rat with increased fidelity and survivability.
For the current model, the anterograde vector was injected into the cell bodies of the somatomotor cortex using bregma as reference18,19. In terms of the spinal injections, the retrograde vector was injected into laminae V-VII, where the CST axon terminals reside20,21. There are many fundamental questions underlying how certain lesion models affect younger animals differently, and how the subsequent recovery diverges from an older animal. This study demonstrates a robust means of studying cervical injuries and the recoverability of forelimb function in neonatal rodents. In contrast, the majority of previous studies have addressed recovery locomotion following lumbar or thoracic injuries5,22,23,24. By pairing the double-viral vector with the novel injection technique described here, this protocol helps mitigate certain issues (i.e., survivability) that may plague neonatal rodent investigations. This method is robust, practical, and versatile: slight variations in the technique will allow for targeting different pathways, i.e., ventral CST, dorsal CST, and the ascending dorsal pathways.
For this system, one locally acting virus (e.g., AAV2) is injected in the region of the neuronal cell bodies of interest. A second retrogradely transported virus that controls the expression of the local virus is injected at the axon terminals for that neuronal population. Thus, by definition, only corticospinal neurons are labeled. The retroAAV-Cre virus was chosen with a constitutively active CMV promoter as the shuttle plasmid is used to generate several AAV serotypes for Cre-dependent expression in several cell types. For cortical injections, AAV2 was chosen with the transgene driven by the synapsin-1 promotor to limit any expression to neurons. Because the 2-viral system relies more on the origin and termination of the neuronal population of interest, several different promoters could be used, if they can drive the expression of the genes of interest within the neuronal population of interest. For example, the excitatory neuronal promoter, CamKII, could be substituted for the synapsin-1. In addition to the use of these AAV serotypes, retrograde transport into immature, and to a much lesser extent, adult corticospinal motor neurons can also be achieved using the high retrograde transportable lentivirus (HiRet)25. HiRet lentiviruses use a chimeric Rabies/VSV glycoprotein to target uptake at the synapse for retrograde transport. Combined with a Tet-On promoter, this 2-viral system supports inducible expression in a retrograde-dependent fashion26,27.
Retrograde viruses insert vectors into the synaptic space of a target neuron, allowing it to be taken up by that cell's axon and transported to the cell body. While lentiviral vectors have previously had tremendous success, providing long-term expression in gene therapy studies, this method pivoted towards adeno-associated viral vectors for a few simple reasons26,28: AAV is more economical, similarly effective, and presents less of a logistical burden, given that it has a lower biosafety level designation29,30,31,32. While AAV2, the most used serotype, demonstrates robust transfection of CST axons, future researchers may note that AAV1 offers some versatility as it labels transynaptically, thus putting forth several possible iterations in future studies33. The final adaptation is to encode the retrograde virus with Cre-recombinase so that multiple anterograde vectors can be introduced simultaneously, thereby reducing unnecessary in-house virus waste and maximizing the likelihood of the DREADDs expressing in the correct orientation.
Ultimately, this protocol demonstrates simultaneous injection into the cortex and cervical spine, specifically targeting the cell bodies and the axon terminals of the corticospinal tract, respectively. High-fidelity transfection is seen in the cerebral cortex and spinal cord. While the protocol described was perfected for Sprague Dawley rats 5 days of age, it is suitable for postnatal days 4-10 with minor adjustments to anesthesia and stereotactic coordinates.
All of the following surgical and animal care procedures have been approved by the Animal Care and Use Committee of Temple University. The protocol described is a survival surgery, and the animals were eventually euthanized by intraperitoneal injection of 100 mg/kg sodium pentobarbital at the completion of their time points.
1. Pre-surgical preparation
2. Anesthesia and surgical site preparation
3. Surgical field and instrument preparation
4. Performing the craniotomy and exposing the somatomotor cortex
Figure 3: A schematic illustration of the cranial injection coordinates (mm) relative to bregma. Please click here to view a larger version of this figure.
5. Loading the virus and positioning the injector
6. Injecting virus into the somatomotor cortex
7. Creating a spinal window for precise spinal cord injections
8. Direct injections into the spinal cord targeting axon terminals
9. Wound closure and postoperative care
Successful injection and transport of the viral vector should result in the transduction of unilateral neurons in the spinal cord and the motor cortex. Figure 4 demonstrates the labeling of layer V CST neurons in the motor cortex of a brain coronal section expressing Cre-dependent-DREADDs-mCherry co-injected with a contralateral spine injection of rCre. The sections were stained with dsRed antibody.
Figure 1: An illustration demonstrating the two-viral injection methods as used in this protocol. Please click here to view a larger version of this figure.
Figure 2: Illustration of the viral constructs used in this protocol, along with the double-floxed inverted orientation being corrected by the retroAAV2-scCRE. Please click here to view a larger version of this figure.
Figure 4: Transduction of neurons in the motor cortex. (A) Magnification of 5x. dsRed immunohistochemistry demonstrating mCherry expression in layer V neurons of the animal's left motor cortex. Scale bar = 500 µm.(B) Magnification of 10x. dsRed immunohistochemistry demonstrating mCherry expression in layer V neurons of the animal's left motor cortex. Scale bar = 200 µm. Please click here to view a larger version of this figure.
Inducible genetic modulation of brain activity with injectable chemogenetic modifiers is a powerful tool in studying the various mechanisms that underlie the recovery from SCI. The accuracy of the targeting for the inducible G-protein-coupled receptors (DREADDs) is further increased when considering that fluorescence tracing validates the anatomical precision in histology. This paper discusses a reliable method for exploring whether or not inhibiting or stimulating select neuronal pathways (with either excitatory or inhibitory DREADDS) results in enhanced axon regeneration or sprouting34,35. Injection of a retrogradely transportable vector into the spinal cord can bring attention to select neuronal populations, either directly or via their synaptic connection, making this method an excellent choice for assessing the neurobiological response to injury.
As illustrated, studying SCI in neonatal models to elucidate any previously unknown discrepancies between pediatric populations and adult populations only serves to complicate the research further. As such, the study designs are narrower. The consensus in neonatal research is that the improved outcomes seen following SCI depend on increased axonal regeneration and increased sprouting until around postnatal day 7 in rodents3,4,5,36. However, this amplified plasticity is not seen beyond postnatal day 10 and recovery plateaus until it represents adult rodent injury models too37,38,40. The underlying mechanisms for the enhanced plasticity in neonates are elusive and remain debated, highlighting the importance of developing easily replicated, survivable, and efficient surgical models to facilitate focused research on neonatal SCI.
For example, some have posited that the disproportionate level of sprouting seen in younger animals negates certain aspects of functional recovery from CST insult19. Ultimately, questions remain whether the spontaneous recovery is due to organic regeneration or simply increased sprouting of aberrant pathways that conveniently bypass the lesion. The protocol described is a relatively straightforward and modular technique that can be used to study corticospinal tract regeneration or sprouting through the artificial inhibition or stimulation of recovery processes with the advent of inducible vectors.
The viruses used in this study were chosen to provide a blueprint for future research investigating the plausibility of influencing recovery from SCI in younger rodents. By design, the transgene expressing mCherry would only label positively under fluorescence if the DREADD (hM3Dq) were expressing simultaneously, as they are both present on the same transgene. While the current protocol does not include behavioral and phenotypic assessments, it has laid the groundwork for successfully investigating DREADD activity in future studies.
The most critical elements to successful injections of viral vectors are knowing the correct anatomy and ensuring sufficient diffusion of virus. With regards to injecting the anterograde vector into the sensorimotor cortex, there are numerous methods described in the literature, including three injections in the vicinity of bregma at a shallow depth (0.5-0.7 mm). Targeting the correct area for the retrograde injection of a vector into the spinal cord requires precision and a deft understanding of the neurobiology of the neurons of interest. The majority of the CST terminals are localized to laminae V-VII throughout the spinal cord grey matter, and successful transfection may require injections at multiple cervical levels41. For instance, segments C4-C7 can be located with distinct landmarks, thus priming the surgical window for routine laminectomies and subsequent injections. Ensuring adequate diffusion of the injected material is dependent on the properties of the vector, volume of the injection, and the density of the neuronal tissue.
Fortunately, the neonatal brain is very receptive to transfection as the lower density allows for a more rapid and disseminated spread of the injected material. The spinal component is more complex, with a significantly tighter injection window. Nevertheless, retroAAV is efficient at transducing the target synapses. It is important to note that the retrograde vector takes time to reach the cell body and flip the DREADD vector into the correct sequence, so the recommended time before conducting behavioral assessments or histological studies is ± 4 weeks from the date of injection. In summary, the retrograde AAV is appropriate, given that it has several immediate advantages, and given that the double-floxed system only fluorescently expresses target neuronal populations. Despite the narrow operative window, the neonatal spinal cord is similarly receptive to transfection and demonstrates florid expression42.
Pediatric spinal cord research is a niche within a field that has many barriers to multilayered investigations. With each new iteration and surgical breakthrough in methodology, the research itself becomes easier, and in turn, the likelihood of uncovering deterministic outcomes increases. Accurately injecting a viral vector into a spinal cord pathway is useful for a host of investigational reasons, and expanding the viral vector technology to include DREADDs is useful for selectively enhancing or attenuating target proteins. The hope is that the improved accuracy from the double-floxed injection system paired with the novel surgical protocol will foster a multitude of similar research goals.
The authors have nothing to disclose.
This work was funded by a fellowship grant from Shriners Hospitals for Children SHC-84706.
#11 scalpel blades | Roboz | RS-9801-11 | For use with the scalpel. |
#10 Scalpel Blades | Roboz | RS-9801-10 | For use with the scalpel. |
1 mL Syringes | Becton, Dickinson and Company | 309659 | For anesthetic SC injection and fluid bolus |
4.0 silk suture | Ethicon | 771-683G | For skin closure |
4.0 Chromic Catgut Suture | DemeTECH | NN374-16 | To re-bind muscle during closing. |
48000 Micropipette Beveler | World Precision Instruments | 32416 | Used to bevel the tips of the pulled glass capillary tubes to form functional glass needles. |
5% Iodine Solution | Purdue Products L.P. | L01020-08 | For use in sterilzation of the surgical site. |
70% Ethanol | N/A | N/A | For sterilization of newly prepared glass needles, animal models during surgical preparation |
Ketamine (Ketaset) | Zoetis | 240048 | For keeping the animal in the correct plane of consciousness during surgery. |
Bead Sterilizer | CellPoint | 5-1450 | To heat sterilize surgical instruments. |
Digital Scale | Okaus | REV.005 | For weighing the animal during surgical preparation. |
Flexible Needle Attachment | World Precision Instruments | MF34G-5 | For cleaning glass needles and loading red oil into glass needles. |
Glass Capillary Tubes | World Precision Instruments | 4878 | For pulled glass needles – should be designed for nanoliter injectors. |
Hemostats | Roboz | RS-7231 | For general use in surgery. |
Medium Point Curved Forceps | Roboz | RS-5136 | For general use in surgery. |
Micromanipulator with a Vernier Scale | Kanetec | N/A | For precise targeting during surgery. |
Microscissors | Roboz | RS-5621 | For cutting glass whisps off of freshly pulled glass capillary tubes. |
Lab Standard Stereotaxic Instrument | Stoelting | 51600 | To hold the neonatal sterotaxic holder in place |
Lab Standard with Mouse & Neonates Adaptor | 51615 | For neonatal skull fixation during cranial surgery and spinal injections | |
Microscope with Light and Vernier Scale Ocular | Leitz Wetzlar | N/A | Used to visualize and measure beveling of pulled glass capillary tubes into functional glass needles. |
MicroSyringe Pump Controller | World Precision Instruments | 62403 | To control the rate of injection. |
Nanoliter 2000 Pump Head Injector | World Precision Instruments | 500150 | To load and inject virus in a controlled fashion. |
Needle Puller | Narishige | PC-100 | To heat and pull apart glass capillary tubes to form glass needles. |
pAAV-CMV-scCre | Wu lab | Cre plasmid | |
pAAV-hSyn-DIO-hM3Dq-mCherry (plasmid #44361) | Bryan Roth’s lab through Addgene | DREADD plasmid | |
Parafilm | Bemis | PM-996 | To assist with loading virus into the nanoinjector. |
PrecisionGlide Needles (25G x 5/8) | Becton, Dickinson and Company | 305122 | For use with the 1mL and 10 mL syringes to allow injection of the animal model. |
Rat Tooth Forceps | Roboz | RS-5152 | For griping spinous processes. |
Red Oil | N/A | N/A | To provide a front for visualization of virus entering tissue during injection. |
Retractors | Roboz | RS-6510 | To hold open the surgical wound. |
Rongeurs | Roboz | RS-8300 | To remove muscle from the spinal column during surgery. |
Scalpel Blade Handle | Roboz | RS-9843 | To slice open skin and fat pad of animal model during surgery. |
Scissors | Roboz | RS-5980 | For general use in surgery. |
Staple Removing Forceps | Kent Scientific | INS750347 | To remove the staples, should they be applied incorrectly. |
Sterile Cloth | Phenix Research Products | BP-989 | To provide a sterile surface for the operation. |
Sterile Cotton-Tipped Applicators | Puritan | 806-WC | To soak up blood in the surgical wound while maintaining sterility. |
Sterile Gauze | Covidien | 2146 | To clean the surgical area and surgical tools while maintaining sterility. |
Sterile Saline | Baxter Healthcare Corporation | 281324 | For use in blood clearing, and for replacing fluids post-surgery. |
Surgical Gloves | N/A | N/A | For use by the surgeon to maintain sterile field during surgery. |
Surgical Heating Pad | N/A | N/A | For maintaining the body temperature of the animal model during surgery. |
Surgical Microscope | N/A | N/A | For enhanced visualization of the surgical wound. |
Surgical Stapler | Kent Scientific | INS750546 | To apply the staples. |
Water Convection Warming Pad | Baxter Healthcare Corporation | L1K018 | For use in the post-operational recovery area to maintain the body temperature of the unconscious animal. |
Weighted Hooks | N/A | N/A | To hold open the surgical wound. |
Liquid bandage | NewSkin | 985838 | To apply along sutures following surgery and encourage wound healing |
Wire Cage Lamp | ZooMed | LF10EC | To help animals recover from anesthesia and retain warm body temperature naturally |